Neovacs SA (FR:ALNEV) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Neovacs SA, a French biotech firm focused on inflammatory and autoimmune diseases, has announced a capital reduction to offset losses by decreasing the nominal share value from 0.005 euro to 0.0005 euro. The company’s share capital now stands at 125,968.0985 euros, divided into 251,936,197 shares. Investors are cautioned about potential share dilution and capital loss due to the company’s dilutive financing operations.
For further insights into FR:ALNEV stock, check out TipRanks’ Stock Analysis page.